[{"address1": "1-8, Doshomachi 3-chome", "address2": "Chuo-ku", "city": "Osaka", "zip": "541-0045", "country": "Japan", "phone": "81 6 6202 2161", "fax": "81 6 6229 9596", "website": "https://www.shionogi.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.", "fullTimeEmployees": 4959, "companyOfficers": [{"maxAge": 1, "name": "Dr. Isao  Teshirogi Ph.D.", "age": 65, "title": "CEO, President & Chairman", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1720672, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Susumu  Mitsumori", "title": "Vice President of Finance & Accounting Department", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ryuichi  Kiyama Ph.D.", "title": "Senior Executive Officer & Senior VP of Administration Division", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Takeshi  Shiota Ph.D.", "title": "Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div.", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yoshimasa  Kyokawa", "title": "Vice President of Corporate Communications & Secretary Office", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Yoshihiro  Furuya", "title": "Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kohji  Hanasaki Ph.D.", "title": "Senior Executive Officer and Senior VP of Supply Supervisory Unit", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John A.  Keller Ph.D.", "age": 59, "title": "Senior Executive Officer and Senior VP of R&D Supervisory Unit", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kazuhiro  Hatanaka", "title": "Senior Executive Officer & Senior VP of Corporate Strategy Division", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Akira  Kato Ph.D.", "title": "Senior Executive Officer & President of Shionogi Pharma Co., Ltd", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.shionogi.co.jp/ir_en/highlight/index.html", "maxAge": 86400, "priceHint": 2, "previousClose": 6.95, "open": 7.1, "dayLow": 7.06, "dayHigh": 7.1, "regularMarketPreviousClose": 6.95, "regularMarketOpen": 7.1, "regularMarketDayLow": 7.06, "regularMarketDayHigh": 7.1, "dividendRate": 0.18, "dividendYield": 0.025899999, "exDividendDate": 1727654400, "payoutRatio": 0.2915, "fiveYearAvgDividendYield": 1.95, "beta": 0.295, "trailingPE": 12.172414, "forwardPE": 2.8582995, "volume": 19856, "regularMarketVolume": 19856, "averageVolume": 246924, "averageVolume10days": 236480, "averageDailyVolume10Day": 236480, "bid": 7.06, "ask": 7.08, "bidSize": 40000, "askSize": 40000, "marketCap": 12124561408, "fiftyTwoWeekLow": 6.22, "fiftyTwoWeekHigh": 9.113333, "priceToSalesTrailing12Months": 0.027337248, "fiftyDayAverage": 6.9816, "twoHundredDayAverage": 7.226405, "trailingAnnualDividendRate": 56.667, "trailingAnnualDividendYield": 8.153525, "currency": "USD", "enterpriseValue": -267739136000, "profitMargins": 0.34851003, "floatShares": 823637633, "sharesOutstanding": 1701379968, "heldPercentInstitutions": 0.0001, "impliedSharesOutstanding": 1717360000, "bookValue": 1519.697, "priceToBook": 0.004645663, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": 0.093, "netIncomeToCommon": 154569998336, "trailingEps": 0.58, "forwardEps": 2.47, "lastSplitFactor": "3:2", "lastSplitDate": 1727827200, "enterpriseToRevenue": -0.604, "enterpriseToEbitda": -1.526, "52WeekChange": -0.13621527, "SandP52WeekChange": 0.22263205, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "SGIOY", "underlyingSymbol": "SGIOY", "shortName": "Shionogi & Co. Ltd.", "longName": "Shionogi & Co., Ltd.", "firstTradeDateEpochUtc": 1448980200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "88f7832a-50b7-3be2-b94c-02b365a69c95", "messageBoardId": "finmb_875364", "gmtOffSetMilliseconds": -18000000, "currentPrice": 7.06, "targetHighPrice": 17.0, "targetLowPrice": 17.0, "targetMeanPrice": 17.0, "targetMedianPrice": 17.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 303405006848, "totalCashPerShare": 356.658, "ebitda": 175421997056, "totalDebt": 11653000192, "quickRatio": 3.849, "currentRatio": 7.067, "totalRevenue": 443517992960, "debtToEquity": 0.889, "revenuePerShare": 259.2615, "returnOnAssets": 0.06807, "returnOnEquity": 0.12056, "freeCashflow": 79178874880, "operatingCashflow": 187547992064, "earningsGrowth": 0.128, "revenueGrowth": -0.04, "grossMargins": 0.86504996, "ebitdaMargins": 0.39551997, "operatingMargins": 0.41037, "financialCurrency": "JPY", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]